Everett, WA – July 14, 2011 – SNBL USA announced today that its Director of Formulations, Lawrence Bush, PhD, will be presenting a poster at the 2011 Colorado Protein Stability Conference to be held at the Beaver Run Resort and Conference Center in Breckenridge, CO, July 19-21, 2011.
Dr. Bush’s poster presentation entitled “Developing a Comprehensive GLP Compliant Program Supporting Dose Formulation Stability Under Conditions of Administration” will be available for viewing and discussion for the duration of the meeting.
For additional information regarding SNBL USA or to request a copy of the poster being presented, please contact SNBL USA at info@snblusa.com.
About SNBL USA, Ltd.
Headquartered in Everett, WA, SNBL USA, Ltd. is a preclinical CRO that specializes in nonhuman primate (NHP) and small animal research. Study programs range from regulatory toxicology to customized study designs and disease models. Specialized programs include reproductive toxicology, safety pharmacology, immunotoxicology and carcinogenicity. SNBL USA’s Laboratory Services division intelligently applies extensive experience, comprehensive scientific capabilities, and modern technology to bring outstanding support to all client research. SNBL USA SRC complements SNBL USA in providing quality NHP resources. Through a commitment to investment and excellence, SNBL USA strives to offer the biotechnology and pharmaceutical industries unparalleled quality in both science and service. For additional information call 425.407.0121 or visit www.snblusa.com.
SNBL USA is a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), one of the largest CROs in Japan. Established in 1957, SNBL currently employs approximately 2,000 team members worldwide and provides full service drug development capabilities ranging from preclinical through clinical services.
